Fig. 4From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trialChange in SCr during study period (SCr values of each group at R20 [Week 20 of the run-in period] were set as 100Â %)Back to article page